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Sporothrix schenkii sensu lato is a rare cause of arthritis. Its course is indolent with lack of constitutional symptoms resulting in
delayed presentation and diagnosis. It is a dimorphic fungus found ubiquitously in sphagnummoss, decaying vegetation, soil, and
hay. Inoculation of dirt into the skin and soft tissues and, in rare instances, inhalation of aerosolized conidia from soil and plants
can lead to infection. Subacute and chronic involvement of skin and subcutaneous tissues is the most common manifestation of
sporotrichosis in immunocompetent hosts. In patients with underlying risk factors (HIV, alcoholism, diabetes mellitus, organ
transplant patients, immunosuppressive medications, steroids, and malignancies), it can often have disseminated visceral,
osteoarticular, meningeal, and pulmonary involvement. Sporothrical arthritis most commonly infects knee joint followed by hand
and wrist joints. A culture of Sporothrix schenkii sensu lato is the gold standard for the diagnosis of sporotrichosis. Itraconazole is
the drug of choice for osteoarticular sporotrichosis. We present a case of sporotrichal arthritis in a patient without skin or lymph
node involvement who underwent treatment with itraconazole resulting in resolution of his symptoms.
1. Case Presentation
A 33-year-old male taxi driver with past medical history
significant only for alcoholism, presented to his family phy-
sician’s office with the chief complaint of left knee pain and
swelling for nine months. He denied any specific injury,
puncture wound, or any systemic symptoms. He denied
contact with animals. Examination of his left knee demon-
strated a moderate-to-severe effusion. He was not tender to
palpation across his bony prominences. He had no medial or
lateral joint line tenderness. He had a range of motion that was
full and symmetric with that of the contralateral side. He had
a negative McMurray’s sign. His knee was stable to liga-
mentous examination. $ere was no erythema or lymph-
adenopathy. X-ray of the left knee showed a joint effusion.
MRI of his left knee also demonstrated a joint effusion with
a popliteal cyst and synovial thickening (Figure 1).
He subsequently underwent aspiration of the effusion in
the office. Synovial fluid was cloudy yellow and blood-tinged.
Fluid analysis showed the following: RBC: 50,200 cells/mcL,
WBC: 4900 cells/mcL (ref range< 150/mcL), PMN: 34% (ref
range 0–25%), lymphocytes: 54%, and monocyte: 10%; no
crystals were observed, and pathological exam was consistent
with hemorrhagic fluid with acute and chronic inflammation.
Bacterial culture did not demonstrate any growth, but fungal
cultures grew branching narrow hyphae with septations and
conidia in a bouquet-like appearance leading to a presumptive
diagnosis of Sporothrix schenkii (Figure 2). $e patient was
admitted to the University of Kansas Hospital for further
management.
$e patient underwent diagnostic left knee arthroscopy,
irrigation, debridement, and major synovectomy. $ere was
no internal derangement of the knee. $ere was no chondral
injury. He had no evidence of a medial-lateral meniscus tear.
His anterior cruciate ligament was intact. $ere was sig-
nificant synovial thickening throughout. Blood counts, liver
biochemistry, coagulation parameters, and renal and thyroid
functions were normal except for elevated liver function tests
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consistent with his history of alcohol use. ESR and CRP were
within normal limits, HIV test was negative, and immu-
nodeficiency workup (humoral immunodeficiency, phago-
cytic disorders, and T-cell immunodeficiencies) was
unrevealing. Abdominal CT done to evaluate for dissemi-
nated disease showed marked diffuse hepatic steatosis. After
the debridement, the patient was started on oral itraconazole
200mg twice daily with a plan to treat for 12 months.
Synovial biopsies obtained during debridement from the
suprapatellar pouch were sent for both microbiology and
pathology. Surgical cultures on Sabouraud dextrose agar
grew Sporothrix schenkii within four days confirming the
initial diagnosis. $e identification was confirmed by
matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry—MALDI-TOF MS (Bruker Daltonics
Biotyper Microflex LT).
All other microbiological investigations of effusion sam-
ples including routine bacterial cultures, acid-fast bacilli (AFB)
cultures, were ultimately negative for any growth. Blood
culturesmultiple times did not reveal any growth. Pathology of
the synovial tissue showed prominent mixed chronic in-
flammation composed of plasma cells and lymphocytes. $ere
were scattered granulomas with central necrosis. Fite’s acid-
fast staining was negative for acid-fast bacilli. GMS stain was
negative for fungal organisms (Figure 3).
Antifungal susceptibility assays were performed by the
broth microdilution method according to the guidelines
recommended by the Clinical Laboratory Standards In-
stitute (CLSI): documents M38-A2 (CLSI, 2002b) (Table 1).
During his subsequent follow-up visits, he reported that
all his symptoms (knee swelling and pain) had improved
with itraconazole, but unfortunately, he continued to drink
excessive amounts of alcohol.
2. Discussion
Sporotrichosis was first diagnosed by Schenck in 1896 at
Johns Hopkins Hospital from a 36-year-old male patient
presenting with right hand and arm lesions [1]. Sporothrix
schenkii sensu lato is a dimorphic fungus. At 25–30°C (in the
environment or the laboratory), the organism grows as
a mold. $e hyphae are narrow with septations and
branching with tapering conidiophores rising at right angles.
$e apex of conidiophores carries many tear-shaped and
round conidia in a bouquet-like appearance forming rosette-
like structures. In vivo at 35–37°C, Sporothrix schenkii
Figure 1: MRI (axial view) of left knee showing synovial thickening
(arrow).
Figure 2: A hyphal form of Sporothrix schenkii from synovial fluid
aspirate cultured on Sabouraud agar. Narrow branching hyphae
(red arrows) giving rise to slender conidiophores (white arrows) at
right angles. $e apex of conidiophores is covered with tear-shaped
conidia in a rosette-like fashion (black arrows). Single conidia can
also be formed along the hyphae.
50 μm
Figure 3: Histopathologic features of excisional biopsy. H/E-
stained sections demonstrate mixed chronic inflammation com-
posed of plasma cells and lymphocytes. Scattered granulomas are
present with central necrosis (×200).
Table 1: Results of antifungal susceptibility testing.
Drugs Results (μg/ml)
Amphotericin B 1
Fluconazole >64
Itraconazole 1
Posaconazole 0.5
Voriconazole >16
Terbinafine 0.008
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creates yeast-like colonies comprising round, oval, or fusi-
form budding cells [2]. Sporothrix schenkii sensu lato is
a complex comprising four related species: S. schenckii sensu
stricto, S. brasiliensis, S. globosa, and S. lurei. S. schenckii
sensu stricto is the most common species associated with
human diseases [3, 4]. In our case, no molecular identifi-
cation was made; therefore, it is necessary to call it Sporo-
thrix schenkii sensu lato.
$e organism grows densely in sphagnum moss,
decaying vegetation, soil, and hay. People involved in out-
door activities are at high risks like gardeners, nursery
workers, farmers, and miners. Accidents that lead to in-
oculation of soil into the skin and soft tissues can lead to
infection. History of trauma is not always present [5]. As in
this case, probably the inoculation happened through mi-
croscopic breaks in the skin or through small injuries the
patient did not remember. $ere are some cases when
Sporothrix schenkii sensu lato caused disease through intact
skin when inoculum was large. In those cases, the infection
was acquired through contact with cats [6, 7]. Sporothrix
schenkii sensu lato can also be transmitted through animal
bites and scratches. In cases of pulmonary sporotrichosis, the
mode of transmission is through inhalation of aerosolized
conidia from soil and vegetations [5].
Subacute and chronic involvement of the skin and
subcutaneous tissues is the most common manifestation of
sporotrichosis in immunocompetent hosts. $e inoculum
load and virulence factors of the strain, immune status of the
patient, as well as the depth of inoculation determine the
various clinical forms of sporotrichosis [8]. In patients with
underlying risk factors (HIV, alcoholism, diabetes mellitus,
organ transplant recipients, malignancies, and use of im-
munosuppressive medications or steroids), it can often have
disseminated visceral, osteoarticular, meningeal, and pul-
monary involvement [5, 9, 10]. Excessive amounts of alcohol
consumption is an important risk factor. Bayer et al. de-
scribed 44 cases of sporotrichal arthritis, of which 38% were
alcoholics. In another report by Howell et al., 10 out of 13
cases of sporotrichal arthritis had a history of significant
alcohol intake [11, 12]. Osteoarticular disease is rare rep-
resenting 3-4% of cases, most often affecting patients with
alcoholism as is the case with our patient [11–14]. It is the
most common extracutaneous form of sporotrichosis [15].
Its course is indolent with lack of constitutional symptoms
resulting in delayed presentation and diagnosis [11].
Osteoarticular form can either follow skin inoculation or
results from hematogenous spread from the lungs. Isolated
involvement of joints without skin lesions is rare. Septic
arthritis is more common than osteomyelitis. Sporotrichosis
most commonly infects the knee joint followed by hand and
wrist joints [11, 13]. It has a propensity to affect small joints
in the hands and the wrist in contrast to other fungal
arthritides (Candida and Coccidioides) [11, 13, 16]. It can be
monoarticular (more common in immunocompetent hosts)
or polyarticular. Other manifestations of osteoarticular
sporotrichosis include granulomatous tenosynovitis and
bursitis [8, 17, 18].
Patients with sporotrichal arthritis usually present with
joint swelling, tenderness, restricted range of motion, and
stiffness. Only a minority of patients have positive constitu-
tional signs, fever, and leukocytosis. Elevated erythrocyte
sedimentation rate is common [19].$e course is indolent with
an average time to diagnosis of 17 months. $e most common
abnormality on X-ray is osteoporosis of contiguous bony
surfaces followed by soft tissue and parasynovial swelling,
cartilage erosion, and punched-out bony lesions [11].
Culture is the gold standard for the diagnosis of spo-
rotrichosis. It consists of isolating the organism from
a clinical specimen. Sabouraud dextrose agar is the medium
of choice. Within days to weeks (in 89% of cases within eight
days), hyphal growth appears at room temperature with
characteristic appearance of conidia (bouquet-like or
rosette-like structures) resulting in the presumptive iden-
tification of Sporothrix schenkii sensu lato [5, 20]. For de-
finitive diagnosis, conversion to the yeast form is required by
subculturing the organism on special media like brain heart
infusion agar, chocolate agar, or blood agar at 35 to 37°C for
5 to 7 days [8, 21]. Another method of identification and
differentiation of closely related Sporothrix species is by
ribosomal protein analysis (obtained directly from fungal
cells) using matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry—MALDI-TOF MS [22].
Histopathologic examination usually reveals mixed gran-
ulomatous and pyogenic inflammation with multinucleated
giant cells. $e typical lesion is noncaseating granulomatous
synovitis, but in some cases, caseating granulomas are seen
mimicking tuberculous arthritis. $e organisms are frequently
present in small numbers, so clinical specimens from patients
infected with Sporothrix schenkii sensu lato often demonstrates
no fungal elements. Either 10% potassium hydroxide, fluo-
rescent antibody staining, Gram stain, or Giemsa stain can be
used, but the sensitivity is low. If yeast forms are present, they
are usually round, oval, cigar-shaped, or fusiform budding cells
[5, 11, 23].
Microdilution test proposed by Clinical Laboratory
Standards Institute (CLSI) is the most commonly used
susceptibility method standardized for Sporothrix schenkii
sensu lato. Even though no MIC breakpoints for dimorphic
fungi have been established, isolates with MIC< 1 g/ml can
be considered susceptible for analytical purposes only [24].
Itraconazole (200mg twice daily by mouth for at least 12
months) is the drug of choice for osteoarticular sporotrichosis
according to the most recent guidelines [25]. Osteoarticular
sporotrichosis has a less favorable response rate to itraconazole
compared with cutaneous or lymphocutaneous sporotrichosis
[26–30]. All forms of sporotrichosis respond to fluconazole
suboptimally [29, 30]. Amphotericin B can be used in ex-
tensive or itraconazole-unresponsive disease with similar ef-
ficacy but with more side effects [11]. Surgical debridement
alone is not effective, and it is not commonly used. In most of
the cases, surgical therapy was performed for diagnostic
purposes as in our case [11, 25].
$e rarity of isolated (without skin and lymph node)
involvement of joints in sporotrichosis as well as the lack of
yeast forms in biopsy specimens results in a delay in di-
agnosis and subsequently in suboptimal treatment leading to
permanent disability and high morbidity. Sporotrichal ar-
thritis should be included in the differential diagnosis of
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chronic monoarthritis or polyarthritis in patients with high-
risk factors and occupation.
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